SCHEMBL2010256

SCHEMBL2010256

CC(C)(C)OC(=O)N[C@H]1CCN(S(=O)(=O)c2cccc3cncc(C(F)(F)F)c23)C1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRD4 O60885 2/20 0.51
ALOX5AP P20292 1/20 0.45
FEN1 P39748 1/20 0.45
CKS1B P61024 1/20 0.40
SKP1 P63208 1/20 0.40
SKP2 Q13309 1/20 0.40
JAK2 O60674 1/20 0.40
JAK1 P23458 1/20 0.40
JAK3 P52333 1/20 0.40
PARP1 P09874 1/20 0.40
MMP2 P08253 1/20 0.39
MMP13 P45452 1/20 0.39
KMT2A Q03164 1/20 0.39
NAMPT P43490 1/20 0.38
KDM4D Q6B0I6 3/20 0.38
DDR1 Q08345 1/20 0.38
PDE10A Q9Y233 1/20 0.38
RORC P51449 2/20 0.38
CTSK P43235 2/20 0.38
SYK P43405 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2010258 1.00 BRD4 (0.51) BRD4ALOX5APFEN1CKS1BSKP1
SCHEMBL2000648 0.89 BRD4 (0.53) BRD4ALOX5APFEN1CKS1BSKP1
SCHEMBL2004217 0.89 BRD4 (0.53) BRD4ALOX5APFEN1CKS1BSKP1
SCHEMBL2003045 0.89 BRD4 (0.53) BRD4ALOX5APFEN1CKS1BSKP1
SCHEMBL2006848 0.89 BRD4 (0.54) BRD4ALOX5APFEN1CKS1BSKP1
SCHEMBL2006846 0.89 BRD4 (0.54) BRD4ALOX5APFEN1CKS1BSKP1
SCHEMBL2008518 0.89 BRD4 (0.54) BRD4ALOX5APFEN1CKS1BSKP1
SCHEMBL1999879 0.88 BRD4 (0.53) BRD4ALOX5APFEN1CKS1BSKP1
SCHEMBL2000977 0.88 BRD4 (0.53) BRD4ALOX5APFEN1CKS1BSKP1
SCHEMBL1999884 0.88 BRD4 (0.53) BRD4ALOX5APFEN1CKS1BSKP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7964613-B2 (S)-3-amino-1-(4-bromo-5-isoquinolinesulfonyl)pyrrolidine; inhibits phosphorylation of myosin regulatory light chain; for spinal canal stenosis, spinal cord injury, rheumatoid arthritis, multiple sclerosis; Rho kinase inhibitors ASAHI KASEI PHARMA CORPORATION (JP) 2011-06-21 US disclosed
EP-2130828-A1 SULFONAMIDE DERIVATIVE Asahi Kasei Pharma Corporation (JP) 2009-12-09 EP disclosed
US-20090048223-A1 Sulfonamide compound ASAHI KASEI PHARMA CORPORATION (JP) 2009-02-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090048223-A1 Sulfonamide compound ALK, AKT1, ARAF BRD4 1825/4885ALOX5AP 3609/4885FEN1 4520/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.